Research programme: GPCR modulators - AstraZeneca/ Heptares Therapeutics

Drug Profile

Research programme: GPCR modulators - AstraZeneca/ Heptares Therapeutics

Alternative Names: AZ-3451; AZ-8838; CNS therapeutics - AstraZeneca/ Heptaris Therapeutics

Latest Information Update: 08 May 2017

Price : $50

At a glance

  • Originator AstraZeneca; Heptares Therapeutics
  • Class Analgesics; Anti-inflammatories; Antibodies; Antineoplastics; Small molecules
  • Mechanism of Action G protein-coupled receptor antagonists; G protein-coupled receptor modulators; PAR 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Inflammation; Metabolic disorders; Pain

Most Recent Events

  • 08 May 2017 Early research in Metabolic disorders and Pain in United Kingdom (Parenteral), before May 2017 (Heptares Therapeutics pipeline, May 2017)
  • 31 May 2011 Early research in Inflammation in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top